FDA Brief

Warning letters Drugs

FDA warning letter to

Laboratoire Druide Inc.

High riskIssued May 29, 2025Posted Jun 10, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Laboratoire Druide that its OTC drugs are adulterated because of inadequate glycerin identity testing, system validation and cleaning.

What happened

FDA inspected Laboratoire Druide's drug manufacturing facility from February 10 to 14, 2025. The agency found inadequate identity testing of incoming components, including high-risk glycerin not tested for diethylene glycol and ethylene glycol; inadequate validation of the system used for production and equipment cleaning; no process validation or bulk hold-time data; and no cleaning validation studies or cleaning logs. FDA reviewed the company's March 6, 2025 response and found it inadequate.

What FDA found

  1. The company did not test each incoming component for identity and relied on supplier certificates without establishing their reliability.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. The company did not adequately test each lot of glycerin for diethylene glycol and ethylene glycol, impurities linked to lethal poisonings.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The company did not adequately validate the system used for production and equipment cleaning; it lacked TOC testing, used an inappropriate conductivity limit, did not monitor for biofilm-forming microbes, and did not investigate out-of-specification microbiology results.

    21 CFR 211.100(a)
  4. The company lacked process validation data, including a bulk hold-time study, for its OTC drugs.

    21 CFR 211.100(a)
  5. The company had no cleaning validation studies or cleaning logs to show shared equipment was adequately cleaned.

    21 CFR 211.67(b)
  6. FDA found the company's quality systems inadequate to ensure CGMP compliance.

    21 CFR parts 210 and 211

What FDA wants

FDA tells the company to respond in writing within 15 working days with corrective actions, including DEG/EG test results from retained high-risk component lots within 30 calendar days, a risk assessment for products within expiry, and plans to fix the system, process and cleaning controls.

Who should pay attention

  • brands that buy finished OTC drugs from this contract manufacturer
  • US distributors and retailers selling its sunscreens, skin protectants, or hand sanitizer
  • suppliers and testing labs in its component supply chain

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk